Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
West German Cancer Center, University Hospital Essen, Essen, Germany.
Heike
H
Richly
Seoul National University Hospital, Seoul, Korea.
Tae Min
TM
Kim
West German Cancer Center, University Hospital Essen, Essen, Germany.
Martin
M
Schuler
Seoul National University Hospital, Seoul, Korea.
Dong-Wan
DW
Kim
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
Simon J
SJ
Harrison
Massachusetts General Hospital, Boston, MA.
Alice T
AT
Shaw
Novartis Institutes for BioMedical Research, Cambridge, MA.
Anthony L
AL
Boral
Novartis Pharma AG, Basel, Switzerland.
Alejandro
A
Yovine
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
Benjamin
B
Solomon
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D013450:Sulfones / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013450:Sulfones; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib